In the quest for relief from the burdens of cancer treatment, individuals often turn to cannabis, seeking answers amidst the chaos of symptoms.
In her talk with Cancer Support Community (CSC) Dr. Brooke Worster, a respected palliative care clinician and Chief Medical Officer at EO, offers insights into the potential benefits of cannabis for cancer patients, highlighting its roles in pain management, nausea alleviation, appetite stimulation, and anxiety relief. Through her expertise, we navigate the complexities of cannabinoids, particularly CBD and THC, uncovering the truths, challenges, and risks in the pursuit of relief and enhanced quality of life.
Navigating a cancer diagnosis is one of the most difficult life challenges a person can face. Two-time cancer survivor and EO spokesperson Ethan Zohn says, “cancer is a disease that touches every part of you as a human being: mental, physical, social, spiritual. You’re always just looking for ways to make yourself feel better.”
Gabapentin and cannabis are two substances frequently used to help manage pain and a range of other health conditions. While gabapentin is primarily used to help treat nerve pain, seizures and shingles-related discomfort, cannabis is well known for its analgesic, anti-inflammatory and relaxation-inducing effects.
A growing body of research illustrates the untapped potential of cannabis for a range of medical uses, like helping to manage pain, stress, sleep and appetite. However, studies also indicate that alternative methods of intake are necessary to create consistent, repeatable effects and to reduce the risks associated with smoking cannabis. According to a scientific review by the Institute of Medicine, “the future of cannabinoid drugs lies not in smoked marijuana but in chemically defined drugs that act on the cannabinoid systems that are a natural component of human physiology.”
Get special offers, event invites and the latest on new care offerings and product releases.
Wise Use for All
© 2024 All rights reserved. Patents pending. EO Care, Inc.
